IGC Pharma (IGC) Non-Current Debt (2010 - 2026)
IGC Pharma (IGC) reported Non-Current Debt of $191000.0 for Q1 2026, up 42.54% year-over-year from $134000.0 in Q1 2025, and down 38.59% quarter-over-quarter from $311000.0 in Q4 2025.
IGC Pharma (IGC) Non-Current Debt (2010 - 2026) Analysis & Trends
IGC Pharma (IGC) has 15 years of Non-Current Debt data on file, last reported at $191000.0 in Q1 2026.
- Non-Current Debt for Q1 2026 came in at $191000.0, up 42.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $191000.0 (up 42.54% YoY), and the FY2026 annual result was $191000.0, up 42.54% from the prior year.
- Non-Current Debt fell to $191000.0 in Q1 2026 per IGC's latest filing, from $311000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $311000.0 in Q4 2025 and troughed at $132000.0 in Q3 2025.
- A 5-year average of $151235.3 and a median of $139000.0 in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt plunged 47.83% in 2022, then surged 132.09% in 2025.
- A 5-year view of Non-Current Debt shows it stood at $141000.0 in 2022, then declined by 2.13% to $138000.0 in 2023, then slipped by 2.9% to $134000.0 in 2024, then surged by 132.09% to $311000.0 in 2025, then plunged by 38.59% to $191000.0 in 2026.
- Business Quant data shows IGC's Non-Current Debt at $191000.0 in Q1 2026, $311000.0 in Q4 2025, and $132000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | IGC Pharma | 28.11 Mn | 27.85 Mn | - | 191,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 191,000.00 |
| Mar 31, 2026 | 191,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Mar 31, 2025 | 134,000.00 |
| Mar 31, 2025 | 134,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 137,000.00 |
| Mar 31, 2024 | 137,000.00 |
| Dec 31, 2023 | 138,000.00 |
| Dec 31, 2023 | 138,000.00 |